Manufacturer's investigation conclusion: a direct correlation between heartmate (hm) 3 left ventricular assist system (lvas), serial number (b)(6) , and the reported cardiac arrhythmia could not be conclusively established through this evaluation.Additionally, the reported pump inflow malposition could not be conclusively established through this evaluation as no images were submitted.It was reported that the patient had multiple episodes of orthostatic hypotension.Additionally, the patient had an episode of ventricular tachycardia with multiple shocks delivered on (b)(6) 2021.The patient had incessant ventricular tachycardia which was reportedly suspected to be due to pump inflow mispositioning.A ventricular tachycardia ablation was scheduled for (b)(6) 2021.Multiple attempts for additional information regarding the reported events were sent to the account.However, no additional information was provided.The patient remains ongoing on heartmate 3 lvas, serial number (b)(6).The relevant sections of the device history records (b)(6) were reviewed and showed no deviations from manufacturing or quality assurance specifications.The heartmate 3 lvas ifu and the heartmate 3 lvas patient handbook are currently available.Section 1 of the ifu, ¿introduction¿, lists potential adverse events, including cardiac arrhythmia, that may be associated with the use of the heartmate 3 left ventricular assist system.Section 5 "surgical procedures" explains how to insert the pump in the ventricle and instructs the user to take care to avoid orienting the inlet towards the interventricular septum as pump function will be compromised in the presence of inlet obstruction.The steps to adjust the orientation of the pump are also outlined in this section.Section 6 of the ifu, ¿patient care and management¿, also lists arrhythmia as a potential late postimplant complication.No further information was provided.The manufacturer is closing the file on this event.
|